Becton, Dickinson and Company (NYSE:BDX) Shares Bought by DLK Investment Management LLC

DLK Investment Management LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,174 shares of the medical instruments supplier’s stock after buying an additional 1,320 shares during the quarter. Becton, Dickinson and Company comprises about 1.9% of DLK Investment Management LLC’s portfolio, making the stock its 23rd biggest holding. DLK Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $4,497,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Becton, Dickinson and Company by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 26,123,450 shares of the medical instruments supplier’s stock worth $6,369,681,000 after purchasing an additional 195,931 shares in the last quarter. Morgan Stanley increased its stake in Becton, Dickinson and Company by 4.5% in the third quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after purchasing an additional 435,168 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Becton, Dickinson and Company by 9.2% in the third quarter. Ameriprise Financial Inc. now owns 3,630,351 shares of the medical instruments supplier’s stock valued at $938,593,000 after purchasing an additional 304,629 shares during the last quarter. Clearbridge Investments LLC increased its stake in Becton, Dickinson and Company by 0.6% in the fourth quarter. Clearbridge Investments LLC now owns 3,154,438 shares of the medical instruments supplier’s stock valued at $769,147,000 after purchasing an additional 19,200 shares during the last quarter. Finally, Norges Bank purchased a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $761,798,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock traded down $1.99 during midday trading on Wednesday, reaching $231.88. The company’s stock had a trading volume of 187,931 shares, compared to its average volume of 1,433,416. The firm has a market capitalization of $67.02 billion, a PE ratio of 51.54, a P/E/G ratio of 2.06 and a beta of 0.44. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. Becton, Dickinson and Company has a fifty-two week low of $224.00 and a fifty-two week high of $287.32. The stock’s 50 day simple moving average is $234.43 and its 200 day simple moving average is $237.93.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter in the previous year, the company posted $2.86 EPS. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, equities research analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 1.64%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Insiders sold 8,615 shares of company stock worth $2,033,381 in the last 90 days. 0.31% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 target price on the stock. Barclays raised their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Finally, StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Friday, June 14th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $280.17.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.